Docs support drug regulator's move to withdraw Olaparib for some cancer patients

Oncologists on Thursday supported the Drug Controller General of India's (DCGI) mandate to state authorities to withdraw AstraZeneca's anticancer generic drug Olaparib over safety concerns.Olaparib is a chemotherapy drug and is used to treat ...

Related Keywords

India ,Delhi ,New Delhi ,Shyam Aggarwal ,Abhishek Shankar ,Astrazeneca Olaparib ,Rajeev Singh Raghuvanshi ,Astrazeneca ,Dr Br Ambedkar Institute Rotary Cancer Hospital ,Department Of Radiation Oncology ,Drug Controller General ,Astrazeneca Pharma India ,Assistant Professor ,Radiation Oncology ,Institute Rotary Cancer Hospital ,Medical Oncology ,Sir Ganga Ram Hospital ,